Tocilizumab

Active substance Tocilizumab
Domain Chronic immune diseases
Reason of inclusion in Horizonscan Geneesmiddelen Biosimilar
Main indication Rheumatism
Extended indication Rheumatoid arthritis (RA), giant lymph node hyperplasia (Castlesman’s disease), polyarticular idioathic juvenile arthritis (PJIA) and systemic juvenile idiopathic arthritis (SJIA).

Product

Current proprietary name RoActemra (Roche)
Proprietary name LusiNEX
Manufacturer Mycenax Biotech
Mechanism of action Interleukin inhibitor

Registration

Registration route Centralised (EMA)
Orphan drug No
Registration phase Clinical trials
Additional comments Momenteel loopt er een fase 1 studie (NCT03522012). SPC RoActemra verloopt op 6 juni 2020.

Therapeutic value

Therapeutic value Potential equal value
Duration of treatment Not found

Expected patient volume per year

Patiëntvolume is niet van toepassing bij generieke geneesmiddelen of biosimilars.

Expected cost per patient per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

Potential total cost per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.